Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Applied Materials, Inc. (AMAT) vs Cassava Sciences Inc (FLNA) Price & Performance

Applied Materials, Inc.Trade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Applied Materials, Inc. vs Cassava Sciences Inc — how do they compare? Applied Materials, Inc. trades at $552.66 (market cap $417.31B), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: Applied Materials, Inc. is far larger — about 8739.5× Cassava Sciences Inc's market cap, and Applied Materials, Inc. pays a 0.4% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

AMATFLNA
Market Cap
$417.31B$47.75M
Sector
TechnologyHealth
52-Week High
$723.00$4.64
52-Week Low
$156.25$0.87
Enterprise Value
$416.34B-$34.93M
Dividend Yield
0.4%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Applied Materials, Inc.

Applied Materials (AMAT) trades at $522.12, down 3.16% on the day, amid a neutral technical signal with support at $510 and resistance at $546. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.86 surpassing the $2.68 forecast. Strong profitability is evident with a net margin of 29.31% and ROE of 39.69%, though valuation ratios like a P/E of 49.45 are elevated. Recent news highlights robust AI-driven demand in semiconductor equipment, with CEO Gary Dickerson calling it the industry's strongest period ever (CNBC, 2026-05-28).

The outlook remains positive given analyst consensus with a $662.82 price target and 76.9% buy ratings, but risks include high valuation sensitivity and cyclical semiconductor capital spending. Revenue growth to $29.0B in 2026 with a projected 29.31% net margin supports upside, though investors should monitor competitive pressures and macroeconomic impacts on tech spending.

Cassava Sciences Inc

FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.

The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Applied Materials, Inc.

Applied Materials is the world's largest supplier of semiconductor manufacturing equipment, providing materials engineering solutions to help make nearly every chip in the world. The firm's systems are used in nearly every major process step with the exception of lithography. Key tools include those for chemical and physical vapor deposition, etching, chemical mechanical polishing, wafer- and reticle-inspection, critical dimension measurement, and defect-inspection scanning electron microscopes.

Read more on AMAT

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA